Characteristics of Participants with Refractory Chronic Cough Enrolled in A Phase 2b Trial of BLU-5937
A. Morice (Cottingham, United Kingdom), J. Smith (Manchester, United Kingdom), S. Birring (London, United Kingdom), L. Mcgarvey (Belfast, United Kingdom), P. Dicpinigaitis (New York, United States), M. Sher (Largo, United States), S. Lanouette (Montreal, Canada), R. Yang (Wilmington, United States), M. Garin (Wilmington, United States), C. Bonuccelli (Wilmington, United States)
Source: International Congress 2022 – Chronic cough, airway diseases and methods
Session: Chronic cough, airway diseases and methods
Session type: Thematic Poster
Number: 178
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Morice (Cottingham, United Kingdom), J. Smith (Manchester, United Kingdom), S. Birring (London, United Kingdom), L. Mcgarvey (Belfast, United Kingdom), P. Dicpinigaitis (New York, United States), M. Sher (Largo, United States), S. Lanouette (Montreal, Canada), R. Yang (Wilmington, United States), M. Garin (Wilmington, United States), C. Bonuccelli (Wilmington, United States). Characteristics of Participants with Refractory Chronic Cough Enrolled in A Phase 2b Trial of BLU-5937. 178
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|